Dennisse Bonilla
Overview
Explore the profile of Dennisse Bonilla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nielsen W, Kharouf F, Grajales C, Thayaparan A, Anderson M, Strand V, et al.
Semin Arthritis Rheum
. 2025 Mar;
72:152684.
PMID: 40056477
Objective: To identify candidate Systemic Lupus Erythematosus (SLE) domains from the literature for consideration towards the development of the SLE Core Outcome Set. Methods: This was a comprehensive scoping literature...
2.
Whittall Garcia L, Gladman D, Urowitz M, Bonilla D, Schneider R, Touma Z, et al.
Lupus Sci Med
. 2024 Nov;
11(2).
PMID: 39613334
Objective: To determine if serum interferon (IFN)-α levels at the time of a lupus nephritis (LN) flare are associated with renal outcomes. Methods: Patients with an LN flare who had...
3.
Johnson S, Alahmari H, Bonilla D, Ahmad Z, Bookman A, Hiraki L, et al.
ACR Open Rheumatol
. 2024 Sep;
6(12):871-877.
PMID: 39348240
Objective: Our objective was to evaluate the development of a systemic autoimmune rheumatic disease (SARD) in undifferentiated and asymptomatic individuals with antinuclear antibodies (ANAs). We comparatively evaluated those who did...
4.
Nielsen W, Strand V, Simon L, Pinsker E, Bonilla D, Morand E, et al.
Semin Arthritis Rheum
. 2024 Aug;
68:152520.
PMID: 39106780
Background: Since the development of the OMERACT Systemic Lupus Erythematosus (SLE) Core Outcome Set (COS) in 1998, many new SLE domains have been identified and measures developed, creating a need...
5.
Gupta A, Johnson S, Barraclough M, Su J, Bingham K, Knight A, et al.
Lupus Sci Med
. 2024 Jul;
11(2).
PMID: 38991833
Objective: To determine if self-reported fatigue, anxiety, depression, cognitive difficulties, health-related quality of life, disease activity scores and neuropsychological battery (NB) cluster into distinct groups in patients with SLE based...
6.
Munoz-Grajales C, Barraclough M, Diaz-Martinez J, Su J, Bingham K, Kakvan M, et al.
Front Immunol
. 2024 Feb;
14:1326751.
PMID: 38332909
Objective: Cognitive impairment (CI) is one of the most common manifestations of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Despite its frequency, we have a limited understanding of the underlying immune mechanisms,...
7.
Nielsen W, Strand V, Simon L, Parodis I, Kim A, Desai M, et al.
Semin Arthritis Rheum
. 2024 Jan;
65:152380.
PMID: 38281467
Background: The Outcome Measures in Rheumatology (OMERACT) Systemic Lupus Erythematosus (SLE) Working Group held a Special Interest Group (SIG) at the OMERACT 2023 conference in Colorado Springs where SLE collaborators...
8.
Barraclough M, Howe A, Soberanis A, Kakvan M, Chattu V, Bani-Fatemi A, et al.
ACR Open Rheumatol
. 2023 Nov;
6(1):21-30.
PMID: 37964675
Objective: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) negatively impacts health-related quality of life leading to activity limitations. This qualitative study aimed to (1) explore the effect of SLE-related...
9.
Dobrowolski C, Barraclough M, Su J, Tanic M, Bingham K, Ruttan L, et al.
Lupus Sci Med
. 2023 Jul;
10(2).
PMID: 37429671
Objective: Cognitive dysfunction (CD) is detectable in approximately 40% of patients with SLE. Despite this high prevalence, there are no approved pharmacological treatment options for this detrimental condition. Preliminary murine...
10.
Kim S, Munoz-Grajales C, Dunn S, Schneider R, Johnson S, Touma Z, et al.
Arthritis Res Ther
. 2023 Feb;
25(1):21.
PMID: 36765391
Background: Elevated levels of interferons (IFNs) are a characteristic feature of systemic autoimmune rheumatic diseases (SARDs) and may be useful in predicting impending symptomatic progression in anti-nuclear antibody-positive (ANA) individuals...